The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.
Participate in the study voluntarily, sign the informed consent form.
Histologically or cytologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma that is deemed unsuitable for radical surgery and/or radical radiotherapy or chemoradiotherapy.
Provide primary or metastatic tumor samples.
At least one measurable lesion (RECIST version 1.1).
With known untreated or active central nervous system (CNS) tumor metastasis, or a history of or current leptomeningeal metastasis.
With symptomatic, poorly controlled, or moderate-to-severe pleural effusion, pericardial effusion, or ascites.
With a history of or concurrent other malignant tumor(s).
Participants with gastrointestinal perforation or fistula, urogenital fistula, or those at risk of fistula within 3 months prior to randomization.